Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance

Joint Bone Spine

Volumn 81, Issue 6, 2014, Pages 544-545

  Toussirot, Éric ^a,b,c   Wendling, Daniel ^a,c   Herbein, Georges ^a,c  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c NONE   (France)

Author keywords

Biologics; Epigenetics; Histone acetylation

Indexed keywords

ADALIMUMAB; ETANERCEPT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; INFLIXIMAB; RITUXIMAB; SIRTINOL; TRICHOSTATIN A;

ANKYLOSING SPONDYLITIS; CLINICAL ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; METABOLISM; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

EID: 84922624569     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.02.011     Document Type: Letter

References (12)

1. Weitzman J. Epigenetics in health and disease. Joint Bone Spine 2012, 79:565.
2. Toussirot E., Khan K.A., Bertolini E., et al. Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?. Joint Bone Spine 2010, 77:395-398.
3. Strietholt S., Maurer B., Peters M.A., et al. Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 2008, 10:219.
4. Grabiec A.M., Tak P.P., Reedquist K.A. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory diseases: should we keep our HATs on?. Arthritis Res Ther 2008, 10:226.
5. Toussirot E., Abbas W., Khan K.A., et al. Imbalance between HAT and HDAC activities in the PBMC of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNFα production. PLoS ONE 2013, 8:e70939.
6. Blanchard F., Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 2005, 10:197-204.
7. Gillepsie J., Savic S., Wong C., et al. Histone deacetylase are dysregulated in rheumatoid arthritis and a novel histone deacetylase-3 selective inhibitor reduces interleukine-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012, 64:418-422.
8. Huber L.C., Brock M., Hemmatazd H., et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007, 56:1087-1093.
9. Kawabata T., Nishida K., Takasugi K., et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R133.
10. Leoni F., Zaliani A., Bertolini A., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxyamic acid exhibits antinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002, 99:2995-3000.
11. Roger T., Lugrin J., LeRoy D., et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor antagonists and to infection. Blood 2011, 117:1205-1217.
12. Katto J., Engel N., Abbas W., et al. Transcritption factor NFκB regulates the expression of the histone deacetylase SIRT1. Clin Epigenet 2013, 5:11.